RNY-derived small RNAs as biomarkers for atherosclerosis-related disorders
AssigneesInstitut National De La Sante Et De La Recherche Medicale (Inserm), Universite Paul Sabatier Toulouse III, Universite De Nice Sophia Antipolis
InventorsMichele Trabucchi, Laurent Martinez, Emanuela Repetto
Life of this patent
Estimating the term…
Abstract
The present invention concerns an in vitro method of diagnosis or prognosis of an atherosclerosis-related disorder by detecting a small Y RNA (s-RNY), as well as the use of an inhibitor of s-RNY as a medicament against atherosclerosis-related disorders. The invention also concerns a method for screening for a compound suitable for the treatment of an atherosclerosis-related disorder.
Claims6
A method of treating an atherosclerosis-related disorder selected from the group consisting of atherosclerosis, chronic kidney disease, cerebrovascular disease, peripheral vascular disease, ischemic heart disease, carotid artery disease, and coronary artery disease in an individual in need thereof, which comprises:
- a) diagnosing or prognosing the individual with an atherosclerosis-related disorder by measuring the level of expression of at least one biomarker consisting of a small Y RNA (s-RNY) in a biological sample of said individual, wherein a level of expression of said biomarker higher than a reference value is indicative that the individual has developed or is at risk of developing an atherosclerosis-related disorder;
- and
- b) administering a therapeutically effective amount of an anti-atherosclerosis drug to said individual diagnosed or prognosed with an atherosclerosis-related disorder, wherein said anti-atherosclerosis drug is selected from the group consisting of bile acid sequestrant, niacin, statins, fibrates, probucol, an s-RNY inhibitor, and combinations thereof.
Dependencies are inferred from the claim text.